


Are mutations in POLG1 involved in MS?

Yael Brantz

Instructor: Prof. Elon Pras

**The Danek Gertner Institute of
Human Genetics**


Increasing Disability



Progressive-relapsing multiple sclerosis

Steady decline since onset with superimposed attacks.


<10% of cases



Secondary progressive multiple sclerosis

Initial relapsing-remitting multiple sclerosis that suddenly begins to have decline without periods of remission.

Follows on from relapsing/remitting



Primary progressive multiple sclerosis

Steady increase in disability without attacks.

10-20% of cases



Relapsing-remitting multiple sclerosis

Unpredictable attacks which may or may not leave permanent deficits followed by periods of remission.

80-90% of cases


Time



Why did the research begin?

- ▶ MS and genetics
- ▶ First patient
- ▶ Mutation – POLG1 gene (P587L, T251I).

Moshe's pedigree



POLG1-related disorders

- ▶ Wide spectrum of disorders:
 - Alpers–Huttenlocher syndrome
 - Childhood myocerebrohepatopathy spectrum disorders
 - Myoclonic epilepsy myopathy sensory ataxia
 - *POLG*-related ataxia neuropathy spectrum disorders
 - Autosomal recessive progressive external ophthalmoplegia
 - Autosomal dominant progressive external ophthalmoplegia
- ▶ MS-like symptoms and manifestations

The mutations in POLG1 gene

- ▶ Cytogenetic Location: 15q25, prevalence – <0.01
- ▶ Pol γ – trimeric protein, catalytic subunit encoded by POLG1
- ▶ The only DNA polymerase active in mitochondria and that can replicate mtDNA
- ▶ Mutations have been related to a wide variety of disorders – **mainly recessive**, also dominant.

Mitochondrial disorders


- ▶ Production of energy by mitochondria depends on:
 - mitochondrial DNA (mtDNA)
 - nuclear genome (nDNA)
- ▶ Disorders involving mtDNA replication:
 - **Qualitative defects** (multiple mtDNA deletions)
 - **Quantitative defects** (mtDNA depletion syndromes)
- Most subunits of the respiratory chain are of **nuclear origin**, as well as enzymes performing critical steps in metabolic pathways (and many more)

What did we do?


- ▶ Looked for relevant patients:
 - Georgians, familial story, preferable Primary Progressive MS
- ▶ Patients with familial background (all ethnic groups)

Nana's pedigree

- Our First positive patient and her familial background
 - Meri's symptoms
 - Sisters' mild symptoms



The patients in the study



► Prevalence in Georgians VS. wide population –
0.1 VS. 0.01


Our thoughts at this point

- ▶ Another mutation in the gene?
- ▶ Where are the homozygotes?

Interesting patient

- ▶ Rivka – 65 YO patient:
 - Progressive external opthalmoplegia – 4 eyelid surgeries
 - “frozen” facial impression
 - familial background – AD
 - Dysphagia for the last 10 years
 - Normal reflexes
 - Walks normally
 - Lateral limitation in eyeball movements
 - coughs while drinking water
- ▶ The full symptoms indicate – Oculopharyngeal muscular dystrophy.

Rivka's pedigree



Oculopharyngeal muscular dystrophy (OPMD)

- ▶ Main symptoms :Ptosis and dysphagia
- ▶ Late onset
- ▶ Other symptoms such as tongue and facial muscle weakness might appear later on
- ▶ Autosomal Dominant or Recessive – PABPN1
 - ▶ Expansion of a GCN trinucleotide repeat
 - ▶ Prevalence – 1:600 among Bukhara Jews in Israel

What's next – PABPN1?

- ▶ Additional meeting with Rivka to discuss the results
 - ▶ Consequences on her daughters
 - ▶ Ethical aspects
- ▶ Search for more PEO patients and test them for OPMD

What's next – POLG1?

- ▶ Expand the prevalence inquiry to 200 Georgian patients
- ▶ Search for more Georgian patients with POLG1 symptoms

QUESTIONS?